ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / OGI / earnings
KZIA (61) SPRB (42) CATX (37) NBP (38) ⌘ Pro Terminal →

Organigram Global Inc. (OGI) Next Earnings Date & Expected ±7.9% Move

$0.93 -2.85% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.92

Organigram Global Inc. (OGI) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY) →
ROARABLE C • HOLD / WATCH Cap $135.4M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on OGI Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is OGI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Organigram Global Inc. (NASDAQ: OGI) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $0.93 (-2.85% 1D, market cap $135.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, OGI ranks #165 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does OGI compare to KZIA and SPRB in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGI carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KZIA (Kazia Therapeutics Limited) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $135.6M) and SPRB (Spruce Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $134.6M). Among the 5-stock peer group, OGI leads on earnings multiple (N/A) while SPRB leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for OGI?
▼

For Organigram Global Inc. (OGI), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #165 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.92 (-0.70%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510062
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-
Cash (12)Whales (13)SEC (13)Macro (15)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE+2.2% Base Target
$2 Bull$1 Base$1 Bear
📬 FREE OGI RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for OGI)Realized 20D OHLCV Swing Band: ±7.9%
Deterministic 5-Pillar Attribution (62/100 Composite)
🔍 WHY OGI SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (24% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 49.6 (NEUTRAL RANGE)

▲ #2 Bullish Driver: Whale & Options Positioning+13/20 pts (21% of score)

20D Institutional Volume Accumulation (±7.9% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
70
Grade B$0.94+0% Next Q
Q2 (-2Q)
67
Grade B-$0.94+0% Next Q
Q3 (-1Q)
65
Grade C+$0.94-1.1% Next Q
Current
62
Grade C$0.93+0.7% Hist 90D α
Trajectory: B (70) → C (62)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the OGI Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, OGI faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($1.04) or 200D SMA ($1.20) invalidates the momentum regime and cuts Target Base ($0.95) toward Bear Floor ($0.74).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $OGI• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “OGI Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 62%NO 38%Trade / Inspect Odds →
NEXT EST. WINDOW: Upcoming Quarter (~28 DAYS)

Historical OHLCV Volatility ±7.9% Swing Band

±$0.07 Expected Swing
$1.00 (-7.9%)Spot $0.93$1.00 (+7.9%)
MODEL EARNINGS SETUP GAUGE

OGI Quantitative Pre-Earnings Setup: 62/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (62/100)Model Risk Weight (38/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating OGI & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on OGI
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
OGI // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -33.09%🛡️ HOLDING TREND SUPPORT
2026-11-02O $0.94H $0.98L $0.93C $0.93VOL 91.3K
RES: $1.44SUP: $0.90SMA50: $1.04SMA200: $1.20
$1.63$1.42$1.21$1.00$0.78RES $1.44SUP $0.90$0.932026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

OGI Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 OGI Butterfly Map → + Track OGI →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on OGI today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for OGI. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for OGI today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (OGI)

Health Care Rank #165 of 1016 ⚔️ KZIA vs OGI Full Matrix →

1. Head-to-Head Health Care Peer Comparison (OGI vs. KZIA, SPRB, CATX, NBP)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Organigram Global Inc. (OGI) ranks #165 by composite RQD confidence (62/100, grade C) and #623 by equity capitalization ($135.4M). Within this direct 5-issuer industry benchmark cohort, OGI leads on earnings valuation at N/A trailing P/E, while SPRB leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. OGI currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
OGI ACTIVE
Organigram Global Inc.
C 62/100 — — — -2.85% $135.4M Benchmark Subject
KZIA
Kazia Therapeutics Limited
C- 61/100 — — — -2.52% $135.6M /kzia-vs-ogi →
SPRB
Spruce Biosciences Inc.
D- 42/100 — — -35.0% -0.92% $134.6M /sprb-vs-ogi →
CATX
Perspective Therapeutics Inc.
D- 37/100 — — -35.0% -1.71% $133.6M /catx-vs-ogi →
NBP
NovaBridge Biosciences
D- 38/100 — — -35.0% -1.24% $139.6M /nbp-vs-ogi →

2. OGI Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Organigram Global Inc. (OGI) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $135.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. OGI Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is OGI stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Organigram Global Inc. (NASDAQ: OGI) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $0.93 (-2.85% 1D, market cap $135.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, OGI ranks #165 in composite RQD confidence.

How does OGI compare to KZIA and SPRB in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), OGI carries a Roarable C (62/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, KZIA (Kazia Therapeutics Limited) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $135.6M) and SPRB (Spruce Biosciences Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $134.6M). Among the 5-stock peer group, OGI leads on earnings multiple (N/A) while SPRB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for OGI?

For Organigram Global Inc. (OGI), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #165 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is OGI trading relative to its 50-day, 200-day, and 52-week technical levels?

OGI last traded at $0.93 (-2.85% on volume of 205,068 shares), positioning the stock -10.58% below its 50-day simple moving average ($1.04) and -22.50% below its 200-day simple moving average ($1.20). Across its 52-week range of $0.85 to $2.24, OGI sits at the 5.8% percentile with a 14-day RSI of 49.6 (NEUTRAL RANGE) and an implied next-earnings move of ±7.9% ($1.00 to $1.00).

OGI Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is OGI's next earnings date?

Based on SEC filing cadence, Organigram Global Inc. (OGI)'s next quarterly reporting window is estimated around Upcoming Quarter.

How much is OGI stock expected to move on earnings?

Volatility modeling currently projects a ±7.9% event move for OGI, spanning a range between $1 and $1.

Direct Sub-Reports: OGI RQD Cockpit OGI 12M Forecast OGI Earnings & Move OGI Dividends & DRIP OGI Insiders & 13F OGI Whale Options OGI Profit Sankey OGI News & Why
ROARABLE RATING BRIEF • RQD 62/100 (C) ✓ STAGE-C NUMBER FIREWALL VERIFIED

OGI — Organigram Global Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:18:04Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, OGI scores 62 out of 100, a letter grade of C, with the verdict label "Roarable Hold — Fair / Balanced Risk-Reward." The five pillars are: Fundamental Cash Engine at 12 of 20 (ROIC 0%; FCF yield 0%); Whale 13F Flow at 13 of 20 (institutional accumulation and options positioning); Insider Conviction at 9 of 20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 15 of 20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 13 of 20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor, the weakest pillar is the cash engine, where the source data reports zero ROIC and zero FCF yield, meaning the rating does not credit the company with current cash generation. The forensic balance sheet and macro fit pillars are the strongest relative to their weight, with a Beta of 1.0 indicating market-level sensitivity and a Piotroski F-Score of 6 of 9 suggesting moderate financial-quality signals. The insider conviction pillar, at 9 of 20, is the lowest score and reflects weaker insider signal flow in the rating's inputs. The overall verdict is a balanced one: upside depends on whether institutional accumulation and cash-generation improvements materialize, while valuation and profitability tradeoffs remain unresolved in the source data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is recorded as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The only sector reference available is Health Care / Biotechnology: Pharmaceutical Preparations. An investor should note that the cannabis-brand discontinuation items suggest product-line exposure, but the source provides no supply-chain nodes to trace its ripple effects.

Open Questions

  • What are OGI's reported revenue, operating income, net income, and free cash flow across recent periods? The financials section is empty, so the 0% margin and ROIC figures cannot be verified against reported results.
  • What is the financial impact of the three-brand discontinuation and cost-saving plan on revenue and margins?
  • Why is the P/E, EPS, and EV/EBITDA data unavailable, and what would valuation look like on any earnings basis?
  • Who are the institutional holders and insiders, and what is the direction of their recent activity? The holders section is empty.
  • What analyst ratings and price targets exist for OGI? The analyst data section is empty.

OGI Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Organigram Global Inc. (OGI) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to OGI Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

OGI Bull vs. Bear Conversation Board — What's Your Call at $0.93?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON OGI 🐻 50% BEARISH CONVICTION
1. Pick Your Side on OGI:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $1.04 (+8.3%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is OGI (C • RQD 62/100) a Buy at $0.96?

Welcome to the OGI (Organigram Global Inc.) Roar Pit. Current RQD Composite is 62/100 (Roarable Hold — Fair / Balanced Risk-Reward) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.75 (-21.9%)
Spot @ $0.96

Pump the brakes on OGI — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on OGI, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Organigram Global Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.10 (+14.6%)
Spot @ $0.96

OGI cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on OGI, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.96 (52-wk range $0.80 - $1.02), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%